246 related articles for article (PubMed ID: 27401840)
1. Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.
de la Motte Rouge T; Pautier P; Genestie C; Rey A; Gouy S; Leary A; Haie-Meder C; Kerbrat P; Culine S; Fizazi K; Lhommé C
Gynecol Oncol; 2016 Sep; 142(3):452-7. PubMed ID: 27401840
[TBL] [Abstract][Full Text] [Related]
2. Role of neoadjuvant chemotherapy in the management of advanced ovarian yolk sac tumor.
Lu Y; Yang J; Cao D; Huang H; Wu M; You Y; Chen J; Lang J; Shen K
Gynecol Oncol; 2014 Jul; 134(1):78-83. PubMed ID: 24582864
[TBL] [Abstract][Full Text] [Related]
3. [Clinical analysis of 12 cases of ovarian yolk sac tumor].
Liu J; Chu HJ; Shan YP; Song WJ; Chen AP
Zhonghua Fu Chan Ke Za Zhi; 2024 Mar; 59(3):210-214. PubMed ID: 38544450
[No Abstract] [Full Text] [Related]
4. Ovarian Yolk Sac Tumor: The Experience of a Regional Cancer Center.
Wang X; Ma Z; Li Y
Int J Gynecol Cancer; 2016 Jun; 26(5):884-91. PubMed ID: 27104939
[TBL] [Abstract][Full Text] [Related]
5. Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base.
Nasioudis D; Chapman-Davis E; Frey MK; Caputo TA; Holcomb K
Gynecol Oncol; 2017 Nov; 147(2):296-301. PubMed ID: 28803748
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of patients with yolk sac tumors of the ovary.
Nawa A; Obata N; Kikkawa F; Kawai M; Nagasaka T; Goto S; Nishimori K; Nakashima N
Am J Obstet Gynecol; 2001 May; 184(6):1182-8. PubMed ID: 11349186
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases.
de La Motte Rouge T; Pautier P; Rey A; Duvillard P; Kerbrat P; Troalen F; Morice P; Haie-Meder C; Culine S; Lhommé C
Eur J Cancer; 2011 Jan; 47(2):175-82. PubMed ID: 20851596
[TBL] [Abstract][Full Text] [Related]
8. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
Derquin F; Floquet A; Hardy-Bessard AC; Edeline J; Lotz JP; Alexandre J; Pautier P; Angeles MA; Delanoy N; Lefeuvre-Plesse C; Cancel M; Treilleux I; Augereau P; Lavoue V; Kalbacher E; Berton Rigaud D; Selle F; Nadeau C; Gantzer J; Joly F; Guillemet C; Pomel C; Favier L; Abdeddaim C; Venat-Bouvet L; Provansal M; Fabbro M; Kaminsky MC; Lortholary A; Lecuru F; Coquard IR; de La Motte Rouge T
Gynecol Oncol; 2020 Sep; 158(3):666-672. PubMed ID: 32624235
[TBL] [Abstract][Full Text] [Related]
9. [The prognostic significance of serum alpha 1-fetoprotein in children and adolescents with malignant extracranial non-testicular germ cell tumors].
Calaminus G; Vesterling-Hörner D; Bökkerink JP; Gadner H; Günther G; Haas HJ; Jürgens H; Teske C; Göbel U
Klin Padiatr; 1991; 203(4):246-50. PubMed ID: 1719268
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome and prognostic factors for yolk sac tumor of the ovary.
Umezu T; Kajiyama H; Terauchi M; Shibata K; Ino K; Nawa A; Kikkawa F
Nagoya J Med Sci; 2008 Mar; 70(1-2):29-34. PubMed ID: 18807293
[TBL] [Abstract][Full Text] [Related]
11. Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour.
Satoh T; Aoki Y; Kasamatsu T; Ochiai K; Takano M; Watanabe Y; Kikkawa F; Takeshima N; Hatae M; Yokota H; Saito T; Yaegashi N; Kobayashi H; Baba T; Kodama S; Saito T; Sakuragi N; Sumi T; Kamura T; Yoshikawa H
Eur J Cancer; 2015 Feb; 51(3):340-51. PubMed ID: 25559616
[TBL] [Abstract][Full Text] [Related]
12. Ovarian malignant mixed germ cell tumor with clear cell carcinoma in a postmenopausal woman.
Yu XJ; Zhang L; Liu ZP; Shi YQ; Liu YX
Int J Clin Exp Pathol; 2014; 7(12):8996-9001. PubMed ID: 25674278
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes and establishment of a novel risk stratification system in patients with ovarian yolk sac tumors.
Li S; Zhang X; Zhang T; Zhang R; Cao D; Xiang Y; Yang J
Gynecol Oncol; 2023 Nov; 178():145-152. PubMed ID: 37865050
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
Inanç SE; Meral R; Darendeliler E; Yasasever V; Onat H
Acta Oncol; 1999; 38(4):505-9. PubMed ID: 10418719
[TBL] [Abstract][Full Text] [Related]
15. Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases.
Mitchell PL; Al-Nasiri N; A'Hern R; Fisher C; Horwich A; Pinkerton CR; Shepherd JH; Gallagher C; Slevin M; Harper P; Osborne R; Mansi J; Oliver T; Gore ME
Cancer; 1999 May; 85(10):2232-44. PubMed ID: 10326703
[TBL] [Abstract][Full Text] [Related]
16. Ovarian Yolk Sac Tumors; Does Age Matter?
Faure Conter C; Xia C; Gershenson D; Hurteau J; Covens A; Pashankar F; Krailo M; Billmire D; Patte C; Fresneau B; Shaikh F; Stoneham S; Nicholson J; Murray M; Frazier AL
Int J Gynecol Cancer; 2018 Jan; 28(1):77-84. PubMed ID: 29194189
[TBL] [Abstract][Full Text] [Related]
17. Yolk sac tumor of the ovary during pregnancy: a case report.
Aoki Y; Higashino M; Ishii S; Tanaka K
Gynecol Oncol; 2005 Nov; 99(2):497-9. PubMed ID: 16051324
[TBL] [Abstract][Full Text] [Related]
18. Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor.
de La Motte Rouge T; Pautier P; Duvillard P; Rey A; Morice P; Haie-Meder C; Kerbrat P; Culine S; Troalen F; Lhommé C
Ann Oncol; 2008 Aug; 19(8):1435-1441. PubMed ID: 18408223
[TBL] [Abstract][Full Text] [Related]
19. Yolk sac tumor in a young girl: a case report.
Razzi S; Luisi S; Gabbanini M; Lazzeri L; Mazzini M; Petraglia F
Gynecol Endocrinol; 2005 Jun; 20(6):334-5. PubMed ID: 16019383
[TBL] [Abstract][Full Text] [Related]
20. Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review.
Chao WT; Liu CH; Lai CR; Chen YJ; Chuang CM; Wang PH
J Ovarian Res; 2018 Jun; 11(1):52. PubMed ID: 29933751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
